secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-05-12T20:03:05+00:00
Accession:  0001628280-26-034082
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M
--------------------------------------------------------------------------

- Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
- Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.
- Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.
- 2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.
- Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/0001628280-26-034082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/tlsi-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-034082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer